Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.5045/br.2017.52.2.95 http://scihub22266oqcxt.onion/10.5045/br.2017.52.2.95 C5503904!5503904!28698844     free     free     free Deprecated: Implicit conversion from float 209.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 209.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 209.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 209.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 209.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       Blood+Res 2017 ; 52 (2): 95-9 Nephropedia Template TP {{tp|p=28698844|t=2017. Dapsone therapy for refractory immune thrombocytopenia patients: a case series |pdf=|usr=}}{{28698844}} gab.com Text Dapsone therapy for refractory immune thrombocytopenia patients: a case series JO: Blood Res http://www.kidney.de/pget.php?&tw=1&pmid=28698844 #FOAvip Background: Dapsone has been recommended as a second-line immunosuppressive agent for patients with immune thrombocytopenia (ITP). Methods: We retrospectively analyzed the efficacy and safety of dapsone therapy in patients with ITP. Results: Nine ITP patients were treated with dapsone at a dose of 50?100 mg/day between May 2013 and March 2016. All patients were refractory to multiple previous treatments, with a median of 7 agents (range, 4?8), and 3 patients had undergone a previous splenectomy. The median pre-treatment platelet count was 4×109/L (range, 3?27×109/L). Only 1 patient (11.1%) responded to dapsone therapy. No severe adverse events were observed, except for 1 case of dapsone hypersensitivity syndrome. Conclusion: Although dapsone is still useful for some patients, it may be ineffective in heavily pretreated patients with profound thrombocytopenia. Twit Text FOAVip Dapsone therapy for refractory immune thrombocytopenia patients: a case series ????Blood Res http://www.kidney.de/pget.php?&tw=1&pmid=28698844 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=28698844 #FOAvip English Wikipedia <ref>{{Cite pmid|28698844}}</ref> Dapsone therapy for refractory immune thrombocytopenia patients: a case series #MMPMID28698844 Lee JY; Lee JO; Jung JY; Bang SM Blood Res 2017[Jun]; 52 (2): 95-9 PMID28698844show ga Background: Dapsone has been recommended as a second-line immunosuppressive agent for patients with immune thrombocytopenia (ITP). Methods: We retrospectively analyzed the efficacy and safety of dapsone therapy in patients with ITP. Results: Nine ITP patients were treated with dapsone at a dose of 50?100 mg/day between May 2013 and March 2016. All patients were refractory to multiple previous treatments, with a median of 7 agents (range, 4?8), and 3 patients had undergone a previous splenectomy. The median pre-treatment platelet count was 4×109/L (range, 3?27×109/L). Only 1 patient (11.1%) responded to dapsone therapy. No severe adverse events were observed, except for 1 case of dapsone hypersensitivity syndrome. Conclusion: Although dapsone is still useful for some patients, it may be ineffective in heavily pretreated patients with profound thrombocytopenia. äDapsone therapy for refractory immune thrombocytopenia patients: a cas(epmc).pdf DeepDyve Pubget Overpricing